A mixed micelle formulation of diazepam was compared with midazolam and diazepam in propylene glycol for evidence of venous intolerance following IV injection. The overall incidence of venous morbidity was 17% for diazepam mixed micelle, 26% for midazolam and 90% for diazepam in propylene glycol. Diazepam mixed micelle is suggested as a preferable alternative to the standard formulation.
The venous tolerance to injectable preparations of diazepam has been extensively studied and it is well known that both the site of Injection and drug vehicle are major determinants of subsequent venous sequelae. I Diazepam is a poorly water soluble (6mg/100ml), lipophilic, weak base, and as such is generally formulated in aqueous preparations with organic solvents or lipid emulsions. Organic solvent preparations may result in problems of physical stability, miscibility, drug absorption to PVC, immunological, as well as local venous intolerance, and are better replaced by other less reactive vehicles where possible.
Diazepam mixed micelle (R05-2807/763) is a new preparation of diazepam, available as a clear, pale yellow solution of 5 mg/ml. 2 The term 'mixed micelle' refers to a normal physiological transport mechanism for lipidsoluble substances in aqueous solution. Bile acids, as detergents, form molecular aggregates called micelles and these bile acids in the correct ratio with lecithin are capable of holding the poorly water soluble cholesterol in aqueous solution as a mixed micelle. The mixed micelle preparation of diazepam (DMM) utilises this physiological principle to solubilise the drug in a colloidal vehicle essentially devoid of organic solvents. A 2 ml ampoule of DMM contains 10 mg diazepam with 177 mg of glycocholic acid and 339 g lecithin in aqueous solution.
The purpose of this study was to compare the venous tolerance of DMM to that of diazepam in propylene glycol (valium) and midazolam. METHOD Ethical approval was obtained from the regional committee and informed consent from 90 female ASA I or II patients undergoing major gynaecological surgery (abdominal or vaginal hysterectomy).
Patients were randomly assigned to one of three treatment groups. At the time of anaesthetic induction, blood pressure and heart rate were recorded and a 23-gauge needle was inserted into a dorsal wrist vein, 10 mg of either valium, DMM or midazolam was injected over 10 seconds and any pain on injection noted by direct questioning. The needle was removed Anllf'SllIesia and IlIlelljjn' Care. J '01. 13, So. 4, .\"ol' (,l1Iber. 1985 and pressure applied with an alcohol swab. Blood pressure and heart rate were recorded at one minute intervals for three minutes and the time taken for the onset of any observable sedative effect noted. After five minutes a 16-gauge cannula was inserted into the opposite arm for the induction of anaesthesia. Intraoperatively no recordings of blood pressure were taken from the arm into which the initial injection had been made.
All patients were seen by an independent anaesthetist 2-3 days and 7-10 days following injection. The venous site was examined and patients were questioned for recall of injection pain.
Comparisons of venous morbidity between groups was by Chi squared test, onset times by the two-tailed Mann-Whitney U test.
RESULTS
The incidence of injection pain and subsequent venous sequelae is shown in Table 1 and Figure 1 .
Both DMM and midazolam produced a highly significant reduction in injection pain when compared to valium (X 2 : p<O.OOl). On the first postinjection visit the incidence of thrombosis was significantly less with valium but by the second visit the only significant difference was between valium and DMM.
The overall frequency of venous morbidity including initial pain on llljection and subsequent venous intolerance was 90070 for valium as compared to 17070 for DMM and 26070 for midazolam.
Of the three preparations DMM had the lowest incidence of venous sequelae noted. For both midazolam and valium, thrombosis and tenderness increased between the two visits although this was not found for DMM.
Median times to onset of effect for the three preparations were 52 seconds for valium, 60 seconds for DMM and 45 seconds for midazolam. While DMM was slower in onset than both midazolam and valium, the di fference was statistically signi ficant only for midazolam. One patient failed to obtain any observable effect from the DMM.
No significant difference (student's t test) was found between the two preparations of diazepam in their effect on the measured cardiovascular parameters (Figure 2 ). Both caused a small drop in systolic and diastolic pressure and a rise in heart rate. Midazolam caused a greater fall in systolic blood pressure and a smaller rise in heart rate. Drawing up and injecting DMM was noted to be easier than valium because of its lower viscosity.
DISCUSSION
The results of this study indicate that a mixed micelle formulation of diazepam leads to a highly significant reduction in both pain on injection and post injection'~ venous sequelae, when compared with t~e standard aqueous preparation with propylene-glycol, ethyl alcohol 10070 and benzyl alcohol 1.5% (valium).
Previous studies vary considerably in the incidence of both injection pain and local venous tolerance; however, allowing for the probable variability in both injection technique and vein assessment, our figures for valium and midazolam are consistent with those of other series. )-5
A time-related increase in the incidence of venous sequelae after both midazolam and valium was found but was not present for DMM. A similar finding has been made previously for the lipid preparation diazemuls. 1 It would appear that both diazemuls and DMM have a comparable low incidence of venous intolerance. 3.4.6 The time to onset of first clinical effect was longer for DMM and although statistically significant only in comparison with midazolam, the slower onset of effect for DMM compared with valium may represent a delay in micelle dissolution. One patient failed to obtain any observable or subjective effect from DMM and while explainable on the basis of wide patient variability, suggests that a study of clinical efficacy is warranted.
No difference was found between the measured cardiovascular parameters for DMM and valium.
With its long life and the presence of active metabolites, valium's clinical applications will undoubtedly be, in part, displaced by the introduction of the shorter-acting water-soluble midazolam. For many procedures of medium duration, diazepam is, however, likely to remain as a useful basal sedative. Diazepam mixed micelle, would not only appear to be a more acceptable alternative to the standard aqueous propylene glycol formulation but may have possible important implications for other lipophilic agents currently available only in organic solvent preparations.
